|
|
|
 |
FDA Approval Activities for this Drug…
Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275/S10 & S12 8/25/03 8/28/03 8/28/03 | Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275/S6 8/26/02 8/30/02 8/26/02 | Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275 3/16/01 4/19/01 8/20/01 | Lumigan Indications: for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive [failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. Lumigan (bimatoprost ophthalmic solution), Allergan | Lumigan (Bimatoprost) Ophthalmic Solution, Allergan, Inc., New or Modified Indication | Latisse (bimatoprost) Ophthalmic Solution, Allergan, Inc., Approval | Lumigan (bimatoprost) Ophthalmic Solution, Allergan, Inc., Approval | Bimatoprost Ophthalmic Solution, Apotex Inc., Tentative Approval | Bimatoprost Ophthalmic Solution, Sandoz Inc., Tentative Approval | Latisse (bimatoprost) Ophthalmic Solution, Allergan, Inc., Labeling Revision | Latisse (bimatoprost) Ophthalmic Solution, Allergan, Inc., Manufacturing Supplement
  
|